Top stories - AstraZeneca withdraws Zactima from EMEA and FDA in lung cancer
-
AstraZeneca withdraws Zactima from EMEA and FDA in lung cancer
added on 28 Oct 2009
Earlier this year I posted about the interim results in non-small cell lung cancer (NSCLC) for AstraZeneca's Zactima (vandetanib) at the ASCO meeting, as part of a review about VEGF inhibitors. Of the 3 trials available for review, one showed some responses and the other two 'had not yet reached...
- Discussing this story:
-
AstraZeneca withdraws Zactima from EMEA and FDA in lung cancer
posted to Pharma Strategy Blog on 28 Oct 2009
Earlier this year I posted about the interim results in non-small cell lung cancer (NSCLC) for AstraZeneca's Zactima (vandetanib) at the ASCO meeting, as part of a review about VEGF inhibitors. Of the 3 trials available for review, one showed some responses and the other two 'had not yet reached...
-
AstraZeneca withdraws Zactima from EMEA and FDA in lung cancer - Pharma Strategy Blog
posted to PharmaGossip on 28 Oct 2009
« Using video in social media to bring science and biotechnology alive | Main October 28, 2009 AstraZeneca withdraws Zactima from EMEA and FDA in lung cancer Earlier this year I posted about the interim results in non-small ...
